Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol versus prolonged-release morphine for chronic cancer pain
2012-001316-35Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cebranopadol in cancer pain (2 arms), sponsored by Grünenthal GmbH. Primary endpoint: Average daily rescue medication intake. Started Aug 2012; status: completed.
02
Drugs
cebranopadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2012-001316-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001316-35.